Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Most safety/indication adverse-effect and FDA-warning claims cannot be verified because the provided label excerpt does not include Sections 1 (Indications) or the relevant full content of Sections 5 (Warnings/precautions). Only dose-modification and prophylaxis-related claims are auditable from the supplied text.
Category Scores
Accurate Statements
Permanently discontinue ZEPZELCA in patients who require a dose interruption of greater than two weeks and in patients who are unable to tolerate 2 mg/m² every 21 days.
Supported by provided excerpt under 2.2 Dosage Modifications for Adverse Reactions.
Dose reductions for adverse reactions are listed in Table 1.
Supported by provided excerpt under 2.2 Dosage Modifications for Adverse Reactions.
Pre-infusion antiemetic prophylaxis may include corticosteroids (dexamethasone 8 mg IV or equivalent) and serotonin antagonists (ondansetron 8 mg IV or equivalent) for ZEPZELCA as a single agent.
Supported by provided excerpt under 2.5 Recommended Prophylactic Medications (ZEPZELCA as a Single Agent).
Unsupported Statements
Lurbinectedin is used to treat certain types of cancer, including small cell lung cancer.
Section 1 (Indications and Usage) is not included in the provided label text, so this indication claim cannot be verified against the supplied prescribing information.
Lurbinectedin is used to treat certain types of cancer, including ovarian cancer.
Section 1 (Indications and Usage) is not included in the provided label text, so this indication claim cannot be verified against the supplied prescribing information.
Lurbinectedin can cause nausea.
While antiemetic prophylaxis is discussed, the provided excerpt does not include a specific adverse reaction statement listing nausea as an adverse reaction for lurbinectedin.
Lurbinectedin can cause vomiting.
The provided excerpt discusses antiemetic prophylaxis but does not provide an adverse reaction listing stating vomiting occurs.
Lurbinectedin can cause fatigue.
The provided excerpt does not include adverse reaction listings for fatigue.
Lurbinectedin can cause diarrhea.
The provided excerpt does not include adverse reaction listings for diarrhea.
Lurbinectedin can cause anemia.
The provided excerpt provided does not include an adverse reaction listing stating anemia.
Lurbinectedin can cause low white blood cell counts.
The excerpt addresses neutropenia (a type of low neutrophil counts) and dose modifications, but it does not explicitly support the broader phrasing 'low white blood cell counts' as an adverse reaction statement.
Low white blood cell counts associated with lurbinectedin can increase the risk of infection.
The excerpt shows neutropenia and dose modifications and references Warnings/Precautions, but the specific infection-risk wording is not included in the supplied text.
Lurbinectedin can cause liver enzyme elevations.
The excerpt includes hepatotoxicity dose modifications and cross-references Warnings/Precautions (5.2) but does not explicitly state 'liver enzyme elevations' as an adverse reaction.
Liver enzyme elevations associated with lurbinectedin can be a sign of liver damage.
No supplied excerpt contains this interpretive linkage/warning wording.
The FDA has warned about the risk of severe low white blood cell counts associated with lurbinectedin.
The supplied excerpt references Warnings and Precautions (5.1) for neutropenia, but it does not provide the actual warning wording to support 'severe low white blood cell counts' phrasing.
The FDA has warned about the risk of severe liver damage associated with lurbinectedin.
The supplied excerpt references hepatotoxicity and Warnings/Precautions (5.2), but it does not include the actual warning wording to verify 'severe liver damage' phrasing.
Patients taking lurbinectedin should have regular blood tests to monitor liver function and white blood cell counts.
The excerpt provides dose modification thresholds and cross-references, but it does not explicitly state monitoring frequency/regularity or 'liver function and white blood cell counts' as an explicit monitoring recommendation.
Contradictions
Important Omissions
Label-backed boxed warning/boxed warning content (if any) and exact warnings language from Section 5 (Warnings and Precautions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several broad safety and FDA-warning/monitoring claims are not verifiable from the supplied prescribing information excerpt. This limits reliability of the safety-related portion of the AI response.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Indication and multiple adverse-effect/FDA-warning/monitoring claims were not auditable against the supplied label text because Sections 1 and full Section 5 content were not provided.
Suggested Improvement
Restrict claims to the supplied label excerpt (e.g., dose discontinuation criteria, Table 1/Table 2 dose modification approach, and the listed antiemetic/G-CSF prophylaxis statements). For safety, use only explicitly stated adverse reactions and monitoring instructions present in the provided label text, or request the missing label sections before asserting them.